NLRC4 methylation and its response to intravenous immunoglobulin therapy in Kawasaki disease: a case control study

Area of Science:

• Epigenetics
• Immunology
• Pediatric Medicine

Background:

• Kawasaki disease (KD) is a critical systemic vasculitis impacting children, necessitating better diagnostic and therapeutic strategies.
• Understanding the molecular underpinnings of KD is vital for improved patient outcomes.
• NLR Family CARD Domain Containing 4 (NLRC4) is a key inflammasome component involved in immune responses.

Purpose of the Study:

• To investigate the potential of NLRC4 promoter methylation as a diagnostic biomarker for Kawasaki disease.
• To explore the association between NLRC4 methylation and disease activity or treatment response in KD.

Main Methods:

• Pyrosequencing analysis of NLRC4 promoter methylation in blood samples from 44 children with initial complete KD and 51 healthy controls.
• Evaluation of methylation at five specific CpG sites within the NLRC4 promoter region.
• Receiver Operating Characteristic (ROC) curve analysis to assess diagnostic accuracy.

Main Results:

• Significantly decreased NLRC4 promoter methylation was observed in KD patients compared to controls across all evaluated CpG sites and average methylation.
• NLRC4 methylation levels showed significant reversal following intravenous immunoglobulin (IVIG) treatment.
• Mean NLRC4 gene methylation demonstrated strong diagnostic capability for KD (AUC=0.844).
• NLRC4 promoter methylation correlated negatively with granulocyte percentage, age, hemoglobin, and erythrocyte volume, and positively with lymphocyte percentage and absolute lymphocyte count.

Conclusions:

• Peripheral NLRC4 hypomethylation plays a role in Kawasaki disease pathogenesis and response to IVIG treatment.
• NLRC4 methylation could serve as a potential biomarker for monitoring KD treatment.
• Further research is needed to fully elucidate the precise functions of NLRC4 methylation in KD.